Operating out of a 50,000 sq. ft. greenhouse in Delta, and a product development facility in Victoria, licensed producer Emerald Health Therapeutics has narrowed the company’s focus to three things: scientific research into the Endocannabinoid System (ECS), medical applications for plant medicine and, most important, medical cannabis.
“We want to provide cannabis in a reliable, standard dose so you get the same effect the first dose, second dose, third dose,” explains Jade Beutler, CEO of Emerald Health Bioceuticals, a division of the company that is focused on non-cannabis phytocannabinoid products formulated to support the ECS. Asked why the company decided to explore non-cannabis products, Beutler explained that its goal is to become global experts in the ECS as well as legitimize the therapeutic use of cannabinoid compounds. “Ultimately this stuff is legitimate medicine and we want to prove that,” he says.
Today, the British Columbian company is part of Emerald Health Group Sciences, which, as noted on the company website, is broadly focused on developing pharmaceutical, botanical and nutraceutical products that will interact with the ECS.
As a result, the company’s product line is diverse and focused as heavily on nutraceuticals, products derived from food sources, as it is on cannabinoids, chemical compounds found in the cannabis plant as well as other plant species, such as Echinacea.
Formerly named Thunderbird Biomedical Inc., the company received its cultivation and sales licences in 2014 and became the fifth federally licensed producer of medical cannabis in Canada. It went public (TSXV: EMH) in Sept. 2014, before undergoing a brand makeover and redesign in 2015.
The company has expanded and grown since 2014 to include wholly-owned subsidiaries Northern Vine Labs, a licensed dealer that performs analytical testing of cannabis and cannabis products as well as Agro-Biotech, a licensed producer in door cultivation facility in Quebec. In early 2018, Emerald announced the launch of Pure SunFarms, a joint venture with Village Farms, the result of which is a 1.1 million sq. ft., state-of-the-art greenhouse that allows the company to produce cannabis year-round by relying primarily on sunlight with supplemental lighting for half the year.
Beyond cannabis, the company is manufacturing supplements meant to support the Endocannabinoid system (ECS), the system of cannabinoid receptors that all vertebrates and invertebrates possess naturally. The ECS is responsible for maintaining homeostasis within the body and supporting the digestive, cardiovascular, nervous and immune systems.
#Watch @BioEmerald CEO, Jade Beutler, answers your questions about the #endocannabinoid (ECS) system and clears up the confusion around #CBD and other non-cannabis botanicals and herbs that support your ECS during his interview with @newhopenetwork. https://t.co/rsJxw4hQ0o pic.twitter.com/tYO5LKslEf
— Emerald Health (@EmeraldHealthHQ) January 16, 2019
Beutler describes the ECS as the body’s bliss bank. “You need to refuel the tank,” Beutler explains while detailing the company’s line of non-cannabis supplements. “Our nervous system and our brain is intrinsically tied to this system. If we make a deposit in our ‘bliss bank’, we’re backing up the ECS.”
There are five flagship products in the bioceuticals line; Endo Bliss, Endo Calm, Endo Inflame, Endo Brain and Endo Sleep—each of which were developed to naturally support the body’s ECS with blends of herbs and botanicals that are part of the company’s proprietary complex.
The Endo product line is available in the U.S. through Whole Foods stores and is expected to be available for Canadian consumers in the spring of 2019, wherever nutraceuticals are available.
With more than 20 years experience in the natural products industry, The Scientific Advisory board at Emerald comprises experts such as Giovanni Appendino, PhD, one of the foremost experts on cannabinoids, along with Dr. Eduardo Muñoz, co-founder of two biotech companies, VivaCell Biotechnology (Spain) and Glactone Pharma AB (Sweden), and an expert in the mechanism of actions of cannabinoids and endocannabinoids.
Note: The author was hired in 2014 to work on communications strategies directly with the then-CEO and founder, Renee Gagnon.
Gill Polard is the co-host of the High Friends podcast and the creator of The Her(B) Life website, which celebrates the feminine cannabis experience through industry interviews, essays and stories.
Want to keep up to date on what’s happening in the world of cannabis? Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.